Drug Eluting Stent Global Market Report 2024 | Size, Share, Outlook, Overview

"The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

Drug Eluting Stent Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.

The Market Size Is Expected To Reach $10.52 billion In 2028 At A CAGR Of 8.4% :

The drug eluting stent market size has grown strongly in recent years. It will grow from $7.05 billion in 2023 to $7.63 billion in 2024 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to the need for improved treatment options, clinical evidence, regulatory approval, healthcare economics, and guidelines and recommendations.

The drug eluting stent market size is expected to see strong growth in the next few years. It will grow to $10.52 billion in 2028 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to an aging population and chronic disease burden, the expansion of indications, healthcare reimbursement policies, global market expansion, and patient-centered care. Major trends in the forecast period include personalized medicine, minimally invasive techniques, emerging healthcare technologies, and next-generation drug formulations.

Request A Sample Of This Report - https://www.thebusinessresearchcompany.com/sample.aspx?id=15557&type=smp

Drug Eluting Stent Market Major Segments
The drug eluting stent market covered in this report is segmented -

1) By Product: Polymer-Based, Polymer-Free
2) By Drug: Sirolimus, Paclitaxel, Zotarolimus, Everolimus, Biolimus, Other Drugs
3) By Scaffold: Cobalt-Chromium, Platinum-Chromium, Nitinol, Biodegradable, Other Scaffolds
4) By Application: Coronary Diseases, Peripheral Vascular Diseases
4) By End-User: Hospitals, Specialty Clinics

Key Driver - The Internet Of Things (IOT) Drives Explosive Growth In The Soft Robotics Market

The rising burden of coronary heart disease is expected to propel the growth of the drug-eluting stent market going forward. Coronary heart disease (CHD) is a condition where the coronary arteries become narrowed or blocked due to plaque buildup, potentially leading to severe complications such as a heart attack or chest pain. Coronary heart disease is increasing due to sedentary lifestyles, poor diets, aging populations, and heightened awareness. Drug-eluting stents (DES) benefit coronary heart disease by effectively opening narrowed or blocked coronary arteries and releasing medication that helps prevent re-narrowing (restenosis) of the artery. For instance, in May 2024, according to the Centers for Disease Control and Prevention, a US-based governmental organization, the percentage of coronary heart disease in adults aged 18 and over in 2020 was 4.6%, which increased to 4.9% in 2022. The rising burden of coronary heart disease is expected to propel the growth of the drug-eluting stench market.

Customise This Report As Per Your Requirements - https://www.thebusinessresearchcompany.com/Customise?id=15557&type=smp

Prominent Trend - Innovation In Advanced Drug-Eluting Coronary Stents

Companies operating in the drug-eluting stent market are focusing on developing innovative delivery systems, such as the dual-layer balloon, to improve patient outcomes and advance the field of interventional cardiology. A dual-layer balloon in a drug-eluting stent system enhances precision in drug delivery and stent deployment by providing better control and uniform drug application to the arterial wall. For instance, in August 2022, Medtronic Plc, an Ireland-based provider of medical supplies, launched Onyx Frontier, the latest generation of drug-eluting coronary stent systems designed to enhance delivery systems that build upon the acute performance and clinical data from the previous generation of Resolute Onyx DES. The Onyx Frontier DES leverages the same best-in-class stent platform as Resolute Onyx, with a broad size matrix to treat patients ranging from 2.0mm to 5.0mm in diameter. The Onyx Frontier DES incorporates notable design enhancements, such as a groundbreaking dual-layer balloon, reduced crossing profile, and improved catheter flexibility. These improvements yield a 16% increase in deliverability over the prior Resolute Onyx DES generation, all while preserving radial strength.

Drug Eluting Stent Market Players
Major companies operating in the drug eluting stent market are Johnson & Johnson Services Inc., Abbott, Medtronic plc, Boston Scientific Corporation, Terumo Corporation, InspireMD Inc., B. Braun Melsungen AG, Cook Group Incorporated, Lepu Medical Technology (Beijing) Co. Ltd., Biotronik, Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, Biosensors International Group Ltd., OrbusNeich Medical Company Limited, Alvimedica Medical Technologies, Hexacath, Elixir Medical Corporation, Translumina GmbH, Cardionovum GmbH, QualiMed Innovative Medizinprodukte GmbH, InSitu Technologies Inc., Acrostak AG, SINOMED Innovation Inc., Svelte Medical Systems Inc.

View The Full Report Here - https://www.thebusinessresearchcompany.com/report/drug-eluting-stent-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the drug-eluting stent market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting stent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Drug Eluting Stent Market Report Structure
3. Drug Eluting Stent Market Trends And Strategies
4. Drug Eluting Stent Market - Macro Economic Scenario
5. Drug Eluting Stent Market Size And Growth
…..
27. Drug Eluting Stent Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.